HemoGenix® is a Compliant Contract Research Service Supplier through Scientist.com
HemoGenix® has been instrumental in helping our world-wide partners bring new drugs to market, evaluate the safety of existing medications, products and environmental agents and assist with quality control and potency testing in the cellular therapy community. The results from our studies have been included in numerous IND applications to the FDA.
Since 2000, HemoGenix® has help small, medium and more than half of the top 50 biopharmaceutical companies with their in vitro toxicity testing and cell biology needs. In addition, with the help of a NCI SBIR grant to develop a high-throughput hematotoxicity assay in 2002 and 2005, HemoGenix® has become the leader in high-throughput hematotoxicity screening and testing with its proprietary HALO®-Tox HT Platform that outperforms traditional assays. Since that time, HemoGenix® has developed toxicity testing platforms for immunotoxicity, hepatotoxicity, cardiotoxicity, neurotoxicity and others. Known for attention to detail, high quality service and one-on-one personal and reliable consultation, HemoGenix® provides the expertise to help in predicting toxicity, risk and safety of a drug or other agent. We look forward to working with you.
The HemoGenix® Team.
To contact us, please click here.
